Bio-Rad Laboratories, Inc. Introduces ReadiLink Antibody Labeling Kits
Published: Feb 28, 2014
Hercules, CA — February 27, 2014 — Bio-Rad Laboratories, Inc. today announced the launch of its ReadiLink antibody labeling kits, one of the market’s simplest antibody conjugation solution for labeling microscale amounts (50–100 µg) of antibody. These kits are ideal for researchers interested in labeling their own antibodies for flow cytometry and cell sorting applications.
Using the ReadiLink antibody labeling kits, researchers can label their antibodies in two easy steps. The protocol takes only 70 minutes, and the labels are as bright and photostable as traditional dyes. Bio-Rad offers 10 different fluorophores whose excitation/emission wavelengths range from UV to infrared.
“The labeling kits will benefit a wide range of researchers,” said Mary Ferrero, Bio-Rad Product Manager in the Gene Expression Division, Life Sciences Group. “ReadiLink antibody labeling kits are ideal for researchers who are using a rare antibody, are interested in an antibody that is not commercially available with the appropriate fluorophore, or who want to label an antibody with a fluorophore that will fit into their multicolor flow cytometric experiment.”
Bio-Rad also offers additional reagents and consumables for each step of flow cytometry experiments, such as the ReadiDrop™ cell viability assays and primary antibodies.
For more information about Bio-Rad’s antibody labeling kits, please visit www.bio-rad.com/antibodylabeling.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) designs, manufactures, and distributes a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs approximately 7,700 people worldwide and had revenues exceeding $2 billion in 2012. For more information, visit our website at www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Bio-Rad Laboratories, Inc.
312-997-2436 x 112
Help employers find you! Check out all the jobs and post your resume.